Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (IMPORTANT)
Implementing Geriatric Assessment for Dose Optimization of CDK 4/6-inhibitors in Older Breast Cancer Patients - a Pragmatic Randomized-controlled Trial (IMPORTANT Trial)
Sponsor: Azienda USL Toscana Centro
A PHASE3 clinical study on Advanced Breast Cancer and Metastatic Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Azienda USL Toscana Centro and has accumulated 8 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — May 2024 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Azienda USL Toscana Centro
- Bröstcancerförbundet
- CareAcross
- Circular Economy Foundation
- Eunomia Ltd
- Hellenic Cooperative Oncology Group
- Helsinki University Central Hospital
- Hospital Clinic of Barcelona
- Institute for Medical Technology Assessment - the Netherlands
- Phaze Clinical Research & Pharma Consulting
- Region Örebro County
- Security Labs Consulting Limited
- Universidad Nacional de Educación a Distancia
- University Hospital, Akershus
- University of Applied Sciences and Arts Northwestern Switzerland
- University of Florence
- University of Patras
- Uppsala County Council, Sweden
- Örebro University, Sweden
For direct contact, visit the study record on ClinicalTrials.gov .